PA-23-230: PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to small businesses. Applications closed on April 5, 2024.
From the official notice on Grants.gov, last changed July 12, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR43 / R44 / U44 / R41
- Clinical trialsNot allowed
- Funded byNIGMS, NCI, NHLBI
- Median yearly award$719,287
- Typical project length2 years
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
- R41, Small Business Technology Transfer (STTR) Phase I. A small business and a research institution test the feasibility of a technology together. Other open R41 notices.
Projects funded under PA-23-230 were run by National Institute of General Medical Sciences (NIGMS, 79 projects), National Cancer Institute (NCI, 73 projects), National Heart Lung and Blood Institute (NHLBI, 66 projects) and National Institute of Allergy and Infectious Diseases (NIAID, 63 projects), and 27 more. Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PA-23-230 in the NIH Guide.
Other notices with this title
Key dates
| Posted | July 12, 2023 |
|---|---|
| Deadline | April 5, 2024 |
| Archived by Grants.gov | May 11, 2024 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the money in the 7 programs behind this notice (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.
Funded under PA-23-230 so far
NIH funded 599 projects under PA-23-230 in fiscal 2024 to 2026, at 543 institutions. The median yearly award was $719,287.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D | Precision Biotools Inc | 2026 | $1.2 million |
| High Content Screening for Bifunctional Chimera Biologics | Heligenics Inc | 2026 | $801,133 |
| Development of Next-gen Chagas DetectTM Plus Rapid test for sensitive and specific diagnosis of Chagas disease | Inbios International, Inc. | 2026 | $974,356 |
| A Device to Prevent Sudden Unexpected Death in Epilepsy (SUDEP) | Soterya, Inc. | 2026 | $395,940 |
| Improving Speed and Cost of Entry for Holographic Optogenetics | Meadowlark Optics, Inc. | 2026 | $1.0 million |
| Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care Settings | Salus Discovery, LLC | 2026 | $999,991 |
| Enhanced endothelialization of nanomatrix coated flow diverter for intracranial aneurysms | Endomimetics, LLC | 2026 | $665,292 |
| Development of novel therapeutics for obesity and type 2 diabetes | Emmyon, Inc. | 2026 | $1.0 million |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Biomedical Research and Research Training grants before
From fiscal 2021 to 2025, Biomedical Research and Research Training (93.859) awarded $15 billion across 11,631 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 186 | $290 million |
| Regents of the University of Michigan | Michigan | 226 | $268 million |
| University of California, San Diego | California | 198 | $264 million |
| Yale Univ | Connecticut | 195 | $250 million |
| University of Wisconsin System | Wisconsin | 169 | $241 million |
Other programs behind this notice
- Arthritis, Musculoskeletal and Skin Diseases Research
- Research Related to Deafness and Communication Disorders
- Discovery and Applied Research for Technological Innovations to Improve Human Health
- Prevention of Disease, Disability, and Death by Infectious Diseases
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PA-23-230 still open?
No. It closed on April 5, 2024.
Who can apply for PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?
Closed April 5, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PA-23-230?
NIH RePORTER lists 599 projects funded under PA-23-230 in fiscal 2024 to 2026, at 543 institutions. The most were at 3DT Holdings, LLC, Syntis Bio Inc, Revel Pharmaceuticals Inc.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before?
The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)